跳转至内容
Merck
所有图片(1)

文件

444264

Sigma-Aldrich

MMP Inhibitor III

The MMP Inhibitor III, also referenced under CAS 927827-98-3, controls the biological activity of MMP. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

别名:

MMP Inhibitor III

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H29N3O4
分子量:
363.45
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥90% (TLC)

形狀

lyophilized solid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
desiccated

顏色

off-white

溶解度

DMSO: 5 mg/mL

運輸包裝

ambient

儲存溫度

−20°C

一般說明

A homophenylalanine-hydroxamic acid based broad-spectrum cell-permeable, reversible inhibitor of matrix metalloproteinases (supplied as a racemic mixture). Inhibits MMP-1 (IC50 = 7.4 nM), MMP-2 (IC50 = 2.3 nM), MMP-3 (IC50 = 135 nM), MMP-7 (IC50 = 10-100 nM), and MMP-13 (IC50 = 1-10 nM).

生化/生理作用

Cell permeable: yes
Primary Target
MMP-1
Product does not compete with ATP.
Reversible: yes
Target IC50: 7.4 nM, 2.3 nM, 135 nM, 10-100 nM, 1-10 nM, against MMP-1, MMP-2, MMP-3, MMP-7, and MMP-13, respectively

警告

Toxicity: Standard Handling (A)

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months (-20°C).

其他說明

Covington, M.D., et al. 2006, Am. J. Physiol. Renal. Physiol.290, F43.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Søren B van Witteloostuijn et al.
Journal of peptide science : an official publication of the European Peptide Society, 23(12), 845-854 (2017-10-24)
Bariatric surgery is currently the most effective treatment of obesity, which has spurred an interest in developing pharmaceutical mimetics. It is thought that the marked body weight-lowering effects of bariatric surgery involve stimulated secretion of appetite-regulating gut hormones, including glucagon-like
Elina Siljamäki et al.
Oncogene, 42(49), 3633-3647 (2023-10-21)
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer. The prognosis of patients with metastatic cSCC is poor emphasizing the need for new therapies. We have previously reported that the activation of Ras/MEK/ERK1/2 and transforming growth factor

相关内容

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门